Which are the symptoms of Crigler-Najjar syndrome?

Crigler-Najjar syndrome is a rare inherited disorder of bilirubin metabolism characterized by persistent, severe unconjugated hyperbilirubinemia, which typically manifests as jaundice shortly after birth. The primary clinical concern is the risk of bilirubin-induced neurological damage (kernicterus) due to the body's inability to effectively process and excrete bilirubin.

What are the primary symptoms of Crigler-Najjar syndrome?

The hallmark symptom of Crigler-Najjar syndrome is intense, persistent jaundice (yellowing of the skin and the whites of the eyes) that appears in the neonatal period. Because the liver enzyme UGT1A1 is either completely absent (Type I) or severely deficient (Type II), unconjugated bilirubin builds up in the blood to dangerous levels. Unlike common neonatal jaundice, the jaundice associated with Crigler-Najjar syndrome does not resolve on its own and requires consistent medical intervention to prevent the accumulation of bilirubin in the brain.

What are the early warning signs and complications to watch for?

Families must be vigilant for signs of acute bilirubin encephalopathy, which can progress to permanent neurological damage known as kernicterus. Early warning signs that require immediate clinical evaluation include:

• Extreme lethargy or difficulty waking the infant for feedings.


• High-pitched crying or unusual irritability.


• Poor muscle tone (hypotonia) or arching of the back and neck (opisthotonus).


• Seizures or sudden changes in alertness.


• Developmental delays in speech or motor skills as the child grows.

How does symptom severity vary between Type I and Type II?

Crigler-Najjar syndrome is classified into two distinct types based on the severity of the enzyme deficiency. In Type I, the UGT1A1 enzyme activity is virtually non-existent, leading to extremely high bilirubin levels—often ranging from 20 to 50 mg/dL—which carry a constant, life-long risk of kernicterus. In Type II (sometimes called Arias syndrome), there is a residual enzyme activity of less than 10%. Patients with Type II Crigler-Najjar syndrome typically have lower bilirubin levels (usually below 20 mg/dL) and are generally less susceptible to kernicterus, though they remain at risk during periods of illness, fasting, or stress.

How does this condition impact daily quality of life?

Living with Crigler-Najjar syndrome requires a rigorous management routine. For many, this involves daily phototherapy sessions—often lasting 10 to 12 hours—to help break down bilirubin through the skin. For our community of 35 members on DiseaseMaps.org, the physical burden of these treatments, combined with the social impact of visible jaundice and the constant need for monitoring, can be significant. Managing Crigler-Najjar syndrome requires a multidisciplinary approach, including pediatric hepatologists, neurologists, and genetic counselors, to ensure that bilirubin levels remain in a safe range and to support the patient’s overall well-being.

When should a patient seek immediate medical attention?

Any sudden increase in jaundice, signs of neurological impairment, or systemic illness (such as a fever or infection) in a person with Crigler-Najjar syndrome warrants an emergency medical consultation. Because stress, fasting, and common illnesses can trigger a sharp rise in bilirubin levels, it is vital to have an emergency action plan in place with your healthcare provider to mitigate the risk of sudden neurological deterioration.

Next steps

• Consult a pediatric hepatologist or a metabolic specialist to establish a routine for blood monitoring and phototherapy.


• Join the Crigler-Najjar syndrome community on DiseaseMaps.org to connect with others who share similar experiences.


• Ensure your primary physician has a clear, documented emergency plan for handling bilirubin spikes during illness.


• Discuss potential long-term treatment options, such as liver transplantation, with your specialist if phototherapy becomes ineffective or burdensome.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment; always seek the advice of your physician regarding any medical condition.

References

• Orphanet: Crigler-Najjar syndrome (ORPHA:205)


• NIH Genetic and Rare Diseases Information Center (GARD): Crigler-Najjar syndrome


• OMIM (Online Mendelian Inheritance in Man): Crigler-Najjar syndrome, Type I (#218800)


• PubMed: Clinical and molecular aspects of Crigler-Najjar syndrome (Review articles)